Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02588586 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Antiretroviral Activity of 3BNC117
A Phase 2 study of HIV-1-infection, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 2
- Study locations
NCT02588586: Completed Phase 2 study of HIV-1-infection, sponsored by Rockefeller University.
NCT02588586 is a Phase 2 study of HIV-1-infection that has completed, run by Rockefeller University. The registered enrollment target is 17 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02588586, a Phase 2 study of HIV-1-infection, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.
Primary Outcome
Viral rebound is defined as confirmed plasma HIV-1 RNA level \> 200 copies/ml in two separate occasions
Conditions Studied
Interventions
- DRUG 3BNC117
- OTHER Antiretroviral Treatment Interruption
Study Locations (2)
New York
- The Rockefeller University - New York
- Weill Cornel Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-04 |
| Phase | Phase 2 |
What the finished NCT02588586 record still lists
NCT02588586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (95% lower).
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 2 interventions - of which 3BNC117 is the first listed.
NCT02588586 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02588586 about?
NCT02588586 is a clinical study titled "A Study of the Safety and Antiretroviral Activity of 3BNC117". This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.
What is the current status of trial NCT02588586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-10. Estimated completion is 2018-04.
What conditions does trial NCT02588586 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT02588586?
The interventions under investigation include: 3BNC117 (DRUG), Antiretroviral Treatment Interruption (OTHER).
Who is sponsoring clinical trial NCT02588586?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02588586 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02588586's enrollment target sits among peer trials
17 65th of 71 higher than 7 of 71 other HIV-1-infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV-1-infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Coronary Vascular Health in Women
RECRUITING · Phase 2
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
PrEPsmart 2-1-1 Pilot
RECRUITING · Phase 2
-
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia